Pharmaron Beijing Co., Ltd.
300759
Classifica tra le azioni
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Prezzo delle azioni
$5.58
Capitalizzazione di mercato
$8.24B
Variazione (1 giorno)
-3.77%
Variazione (1 anno)
28.36%
Paese
CN
Scambia Pharmaron Beijing Co., Ltd. (300759)
Categoria
Healthcare
Ricavi di Pharmaron Beijing Co., Ltd. (300759)
Ricavi nel Jun 2026 TTM: $2.28B
Secondo gli ultimi rapporti finanziari di Pharmaron Beijing Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a $2.28B. Nel 2024, l'azienda ha registrato ricavi di $1.68B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $1.63B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Pharmaron Beijing Co., Ltd. da 2014 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $2.28B | 12.93% |
| 2025 | $2.01B | 19.79% |
| 2024 | $1.68B | 3.18% |
| 2023 | $1.63B | 9.52% |
| 2022 | $1.49B | 27.08% |
| 2021 | $1.17B | 49.03% |
| 2020 | $785.83M | 45.64% |
| 2019 | $539.57M | 27.62% |
| 2018 | $422.78M | 19.90% |
| 2017 | $352.61M | 49.80% |
| 2016 | $235.38M | 35.50% |
| 2015 | $173.71M | 36.12% |
| 2014 | $127.61M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 454.89% |
US
|
|
| $2.23B | -2.07% |
US
|
|
| $15.74B | 592.03% |
AU
|
|
| $10.11B | 344.41% |
BE
|
|
| $6.02B | 164.66% |
NL
|
